Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 3
2012 4
2013 8
2014 12
2015 12
2016 9
2017 19
2018 14
2019 14
2020 17
2021 21
2022 14
2023 16
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

145 results

Results by year

Filters applied: . Clear all
Page 1
Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer.
Heidegger I, Fotakis G, Offermann A, Goveia J, Daum S, Salcher S, Noureen A, Timmer-Bosscha H, Schäfer G, Walenkamp A, Perner S, Beatovic A, Moisse M, Plattner C, Krogsdam A, Haybaeck J, Sopper S, Thaler S, Keller MA, Klocker H, Trajanoski Z, Wolf D, Pircher A. Heidegger I, et al. Mol Cancer. 2022 Jun 18;21(1):132. doi: 10.1186/s12943-022-01597-7. Mol Cancer. 2022. PMID: 35717322 Free PMC article.
STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway.
Pencik J, Philippe C, Schlederer M, Atas E, Pecoraro M, Grund-Gröschke S, Li WJ, Tracz A, Heidegger I, Lagger S, Trachtová K, Oberhuber M, Heitzer E, Aksoy O, Neubauer HA, Wingelhofer B, Orlova A, Witzeneder N, Dillinger T, Redl E, Greiner G, D'Andrea D, Östman JR, Tangermann S, Hermanova I, Schäfer G, Sternberg F, Pohl EE, Sternberg C, Varady A, Horvath J, Stoiber D, Malcolm TI, Turner SD, Parkes EE, Hantusch B, Egger G, Rose-John S, Poli V, Jain S, Armstrong CWD, Hoermann G, Goffin V, Aberger F, Moriggl R, Carracedo A, McKinney C, Kennedy RD, Klocker H, Speicher MR, Tang DG, Moazzami AA, Heery DM, Hacker M, Kenner L. Pencik J, et al. Among authors: heidegger i. Mol Cancer. 2023 Aug 12;22(1):133. doi: 10.1186/s12943-023-01825-8. Mol Cancer. 2023. PMID: 37573301 Free PMC article.
Drug-Drug Interactions in Prostate Cancer Treatment.
Hebenstreit D, Pichler R, Heidegger I. Hebenstreit D, et al. Among authors: heidegger i. Clin Genitourin Cancer. 2020 Apr;18(2):e71-e82. doi: 10.1016/j.clgc.2019.05.016. Epub 2019 May 27. Clin Genitourin Cancer. 2020. PMID: 31677899 Review.
Cytoreductive Radical Prostatectomy for Metastatic Hormone-sensitive Prostate Cancer-Evidence from Recent Prospective Reports.
Rajwa P, Zattoni F, Maggi M, Marra G, Kroyer P, Shariat SF, Briganti A, Montorsi F, Heidegger I, Gandaglia G; EAU-Young Academic Urologists (YAU) Prostate Cancer Working Party. Rajwa P, et al. Among authors: heidegger i. Eur Urol Focus. 2023 Jul;9(4):637-641. doi: 10.1016/j.euf.2023.01.011. Epub 2023 Jan 23. Eur Urol Focus. 2023. PMID: 36697321 Review.
Atezolizumab for PD-L1-Selected Patients with NSCLC.
Pircher A, Heidegger I, Wolf D. Pircher A, et al. Among authors: heidegger i. N Engl J Med. 2021 Feb 11;384(6):584. doi: 10.1056/NEJMc2032432. N Engl J Med. 2021. PMID: 33567201 No abstract available.
Hereditary prostate cancer - Primetime for genetic testing?
Heidegger I, Tsaur I, Borgmann H, Surcel C, Kretschmer A, Mathieu R, Visschere P, Valerio M, van den Bergh RCN, Ost P, Tilki D, Gandaglia G, Ploussard G; EAU-YAU Prostate Cancer Working Party. Heidegger I, et al. Cancer Treat Rev. 2019 Dec;81:101927. doi: 10.1016/j.ctrv.2019.101927. Epub 2019 Nov 11. Cancer Treat Rev. 2019. PMID: 31783313 Review.
145 results